Showing 1191-1200 of 4117 results for "".
Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/annual-trends-in-medicare-part-d-prescription-claims-for-guselkumab-20182020/28861/Jachin Wu, MD, FAAD, and colleagues talk about Medicare claims for guselkumabDermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markePhysician Spotlight: J. Mark Jackson, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-j-mark-jackson-md/23505/Physician Spotlight: Adam J. Friedman, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-adam-j-friedman-md/23375/Physician Spotlight: Adam J. Friedman, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-adam-j-friedman-md-1/23614/Physician Spotlight: J. Matthew Knight, MD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-j-matthew-knight-md-faad/20561/Dermatologists must act now to extinguish burnout or risk dire consequences.Physician Spotlight: George J. Hruza, MD, MBA, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-george-j-hruza-md-mba-faad/23062/Clinical Conversations: Discover Dr J Scott Boswell’s Perspective on Redefining PN and AD Through a Neuroimmune Lens
https://practicaldermatology.com/videos/nemluvio-peer-network/clinical-conversations-discover-dr-j-scott-boswells-perspective-on-redefining-pn-and-ad-through-a-neuroimmune-lens/56421/In this Clinical Conversations newsletter, Dr Scott Boswell shares how reframing prurigo nodularis (PN) and atopic dermatitis (AD) as neuroimmune-driven conditions has shaped his clinical philosophy. He shares his 3‑step approach to patient communication, highlights real‑world treatment journeys inJournal Club: Dupilumab and Atopic March
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Reduced